Medication info
Pregabalin Capsule 150 mg (Pregabalin)

Pregabalin Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Myeongin Pharmaceutical Co., Ltd.
Appearance
White or light yellow powder contained in a white hard capsule with a white upper and lower part
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201109029 · Notified 2011.10.24 · Insurance code 651903590

Summary

Main use
Treatment of neuropathic pain; adjunctive treatment of partial seizures of epilepsy; treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
The total daily dose of this medicine, expressed as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Method of administration Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated under method of administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended. Adolescent patients aged 12 ~17 years: Administration is not recommended.

Ingredients

Manufacturer
Myeongin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain; adjunctive treatment of partial seizures of epilepsy; treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct therapy in patients with epilepsy who have partial seizures, regardless of whether they have secondary generalization. Additionally, it is effective in treating chronic pain syndromes such as fibromyalgia. In summary, this drug is used in the management of neuropathic pain, as an adjunct treatment for epileptic seizures, and to improve symptoms of fibromyalgia.

How to take

Adult dose

The total daily dose of this medicine, expressed as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Method of administration Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated under method of administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended. Adolescent patients aged 12 ~17 years: Administration is not recommended.

Precautions

This drug may increase the risk of suicidal thoughts or behavior, so if depression or mood changes occur during treatment, consult a doctor immediately. Patients who are allergic to the components of this drug or have specific genetic metabolic disorders should not take it. Diabetic patients should be aware that dosage adjustments may be needed for blood sugar control due to weight gain. If severe allergic reactions such as angioedema occur, discontinue use immediately and inform healthcare personnel. Elderly patients should exercise caution at the beginning of treatment due to the risk of falls from dizziness or drowsiness. Blurry vision or changes in eyesight may occur, and if these symptoms appear, consult a doctor. Abrupt discontinuation of this medication may cause withdrawal symptoms such as insomnia, headache, and anxiety, so the dosage should be gradually adjusted according to the doctor's instructions. Patients with a history of drug abuse may have a higher risk of abusing this medication, so caution is needed during use. Patients with heart or kidney diseases should consult healthcare personnel before taking this drug, especially heart failure patients require careful administration. Caution is necessary when taking this medication in combination with opioid analgesics as it may increase central nervous system depressant effects. Patients with respiratory or neurological disorders, kidney impairment, and the elderly may need dosage adjustments due to the risk of severe respiratory depression. During early pregnancy, there may be a risk of congenital malformation in the fetus, so it is recommended that pregnant women avoid this medication, and women of childbearing age should use effective contraception. Breastfeeding women should consider stopping breastfeeding or discontinuing this medication as it can be passed into breast milk. It is safer to avoid hazardous activities such as driving or operating machinery until dizziness or drowsiness resolves after taking this medication. Severe skin reactions may occur, so if symptoms such as rash, redness, or blisters appear, discontinue use immediately and inform healthcare personnel. Overdose may present symptoms such as drowsiness, confusion, and depression; treatment such as dialysis may be required if necessary. Keep out of reach of children and do not transfer to another container for safety.

Side effects

  • Suicidal impulses
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 206 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • weight gain
  • rhinitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • depression
  • relief
  • decreased libido
  • insomnia
  • depersonalization
  • hyperesthesia
  • restlessness
  • anxiety
  • mood swings
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to restrain
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination impairment
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory deficits
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • reflex reduction
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • dysgraphia
  • blurred vision
  • diplopia
  • peripheral vision loss
  • visual disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • conjunctival edema
  • decreased vision
  • ocular pain
  • eye fatigue
  • increased lacrimation
  • eye irritation
  • mydriasis
  • during vibrations
  • changes in depth perception of vision
  • strabismus
  • brightness of vision
  • dizziness
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • shortness of breath
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • oropharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • hypersalivation
  • gastroesophageal reflux disease
  • oral sensory deficits
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle twitching
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait disturbances
  • falls
  • feeling drunk
  • sensory disturbances
  • fatigue
  • tightness in the chest
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • depression
  • agitation
  • restlessness
  • seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a sealed container. It is best to maintain the storage temperature between 15 to 30 degrees Celsius. Proper storage can help sustain the effectiveness of the medication over time.

Appearance and packaging

Appearance

White or light yellow powder contained in a white hard capsule with a white upper and lower part

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.